ClinicalTrials.gg
CompletedNCT01379300Updated Oct 2, 2015

A Study to Investigate Biomarkers After Single Doses of Anticoagulants in Healthy Young Male and Healthy Elderly Participants (MK-0000-216 AM1)

A Phase 1 interventional study of dabigatran etexilate and rivaroxaban in Thrombosis, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-10-02.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 30 studies testing rivaroxaban in Thrombosis — 4 open to participants now, 4 under way, 1 of them phase 3. Rivaroxaban · Thrombosis.

Enrollment
22nd of 30
42 · median 84
Started
2011
the only one that year
Phase 1
7 of 30
1 open now
Registered
5th of 30
by date

Among the 30 studies testing rivaroxaban in Thrombosis, this one is the 22nd largest by enrollment, is the only one that started in 2011, is one of 7 in phase 1, and was the 5th registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

4 of the 30 studies testing rivaroxaban in Thrombosis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About rivaroxaban

Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies testing rivaroxaban in Thrombosis, or all of them as a file.
02

Study summary

This is a study to investigate biomarkers after single oral doses of the anticoagulant agents dabigatran etexilate and rivaroxaban in healthy young male subjects and in healthy elderly subjects.

03

Conditions studied

  • Thrombosis

Keywords

  • Hemophilia B
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria for non-hemophilia participants:

Panel A

  • Male or female between 65 to 85 years of age

Panel B

  • Male between 18 to 45 years of age

Both Panels

  • Weight of ≥50 kg and ≤110 kg
  • In good health
  • No abnormality on (ECG)
  • Nonsmoker and/or has not used nicotine or nicotine-containing products for at least approximately 6 months

Exclusion criteria for non-hemophilia participants:

  • History of stroke, chronic seizures, or major neurological disorder
  • History of clinically significant endocrine, gastrointestinal (including peptic ulcer disease), cardiovascular, hematological, hepatic, immunological, renal, respiratory, or genitourinary abnormalities or diseases
  • History of malignant neoplastic disease, with the exception of adequately treated non-melanomatous skin carcinoma or other that have been successfully treated ≥10 years prior to the study
  • History of a thrombotic or -related disorder including prior deep venous thrombosis or pulmonary embolus
  • Use of warfarin, coumadin, heparin, aspirin, dabigatran etexilate, rivaroxaban or dipyridamole within 2 weeks
  • History of poor wound healing
  • Unable to refrain from or anticipates the use of any medication, including aspirin and aspirin-containing products, all non-steroidal anti-inflammatory drug (NSAID)-containing products (including pain, cold and allergy products, etc.) and including prescription and non-prescription drugs or herbal remedies (such as St. John's Wort [Hypericum perforatum]) beginning approximately 2 weeks (or 5 half-lives) prior to initiation of the treatment periods, throughout the study until the post-study visit
  • Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) per day
  • Consumption of excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, or other caffeinated beverages per day
  • Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or participation in another study within 4 weeks
  • History of significant multiple and/or severe allergies (including latex allergy), or an anaphylactic reaction or significant intolerability to prescription or non-prescription drugs or food, including dabigatran etexilate and rivaroxaban
  • Current regular user (including illicit drugs or has a history of drug [including alcohol] abuse within approximately 6 months
  • History (including family history if hereditary) or symptoms of clinically relevant bleeding disorder
  • Organic lesion at risk of bleeding (e.g., aneurysm, cavernous hemangioma, arterio-venous malformation)
  • History of frequent epistaxis or has recurrent or active gingivitis or hemorrhoids

Inclusion criteria

Inclusion criteria for hemophilia participants:

  • Male with diagnosis of hemophilia B between 18 to 64 years of age
  • Weight of ≥110 lbs and ≤300 lbs
  • Has not received clotting factor in the 7 days prior to blood sampling
  • No active bleeding event
  • No procedure or surgery in the past 8 weeks
  • Judged to be in good health based on medical history
  • Has not smoked more than 2 cigarettes per day for at least approximately 1 week prior; has not smoked a pipe or cigar or chewed tobacco for at least 3 days prior
  • Can refrain from the use of all NSAIDs (e.g., Advil, Aleve, aspirin), all NSAID-containing products (including pain, cold, and allergy products, etc.), herbal meds or drugs for 7 days prior to the date of study procedure

Exclusion criteria

Exclusion criteria for hemophilia participants:

  • endocrine, gastrointestinal (including peptic ulcer disease), cardiovascular, hematological (except factor IX deficiency), immunological, renal, respiratory, neurological or genitourinary abnormalities or diseases
  • History of malignant neoplastic disease, with the exception of adequately treated non-melanomatous skin carcinoma or other that have been successfully treated ≥10 years prior to the study
  • Consumption of excessive amounts of alcohol, defined as greater than 3 glasses of alcoholic beverages (1 glass is approximately equivalent to: beer [284 mL/10 ounces], wine [125 mL/4 ounces], or distilled spirits [25 mL/1 ounce]) within 24 hours prior to study procedures
  • Major surgery, donation or loss of 1 unit of blood (approximately 500 mL) or participation in another study within 7 days prior to the date of study procedures
  • Current regular user (including illicit drugs or has a history of drug [including alcohol] abuse within approximately 6 months
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    Dabigatran

    Single 150-mg dose of dabigatran etexilate

    Drug: dabigatran etexilate

  • Experimental
    Rivaroxaban

    Single 20-mg dose of rivaroxaban

    Drug: rivaroxaban

  • No intervention
    No intervention

    No study drug will be administered

Interventions

  • dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration

  • rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration

06

What researchers measure

Primary outcomes

  1. Endogenous thrombin potential by Thrombin Generation Assay (TGA)-2a assay

    Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose

  2. Level of fibrin degradation product (D-dimer)

    Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose

  3. Level of fibrinopeptide A (FPA)

    Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose

  4. Level of prothrombin split products (F1+2)

    Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose

  5. Level of thrombin-antithrombin complex (TAT)

    Time frame: From up to 2 hours pre-dose to up to 24 hours post-dose

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2011
First posted
Jun 23, 2011
Start
May 2011
Primary completionActual
Dec 2011
CompletionActual
Dec 2011
Last update
Oct 2, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 2, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01379300
Responsible party
Sponsor
First posted
Jun 23, 2011
Start date
May 2011
Primary completion
Dec 2011
Completion
Dec 2011
Last update
Oct 2, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Dabigatran · Rivaroxaban

Start the discussion